Table 3.
Gastroduodenal events induced by non-steroidal anti-inflammatory drugs.
| No. | Study | Drugs | Study Design | Country | Total Studied Patients | Gastroduodenal Perforation (%, Number) | RR (95% CI) |
|---|---|---|---|---|---|---|---|
| 1 | Bombardier et al. (2000) [19] | Rofecoxib and naproxen | Cohort | Twenty-two countries. | 8076 | 6.6% (533) | 0.4 (0.2–0.8) |
| 2 | Yeomans et al. (2017) [20] | Colecoxib, ibuprofen, and naproxen | Cohort | United States, Canada, Australia, Brazil, Colombia, Costa Rica, Mexico, Panama, Peru, Philippines, Taiwan, Hong Kong, and Ukraine. | 24,081 | 1.7% (409) | 0.44 (0.28–0.7) |
| 3 | Cheatum et al. (1999) [22] | >5 NSAID | Cross sectional | Fourteen countries that abided by the Declaration of Helsinki. | 1826 | 37.1% (676) | 0.811 (0.067–3.4) |
| 4 | Ishikawa et al. (2012) [21] | >5 NSAID | Consecutive cross sectional | Japan | 305 | 50% (153) | 1.715 (1.98–18.89) |
| 5 | Vonkeman et al. (2007) [12] | >5 NSAID | Cohort | Germany | 10,402 | 1% (104) | 0.498 (0.23–0.78) |